Medpace (NASDAQ:MEDP) Downgraded to “Hold” Rating by Wall Street Zen

Medpace (NASDAQ:MEDP) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities analysts also recently commented on the stock. Rothschild Redb downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Mizuho raised their price objective on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a report on Friday, October 24th. Robert W. Baird set a $613.00 target price on Medpace in a research report on Friday, October 24th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Finally, Truist Financial set a $555.00 price target on Medpace in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $490.82.

Medpace Stock Up 1.5%

MEDP stock opened at $568.36 on Friday. Medpace has a twelve month low of $250.05 and a twelve month high of $626.26. The firm has a market cap of $16.01 billion, a price-to-earnings ratio of 39.75, a PEG ratio of 2.11 and a beta of 1.43. The business’s fifty day simple moving average is $574.72 and its two-hundred day simple moving average is $470.83.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business’s revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the firm earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts expect that Medpace will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In related news, President Jesse J. Geiger sold 21,503 shares of the company’s stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at $8,934,900. This represents a 58.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO August J. Troendle sold 59,025 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the sale, the chief executive officer directly owned 774,602 shares in the company, valued at approximately $470,787,603.56. The trade was a 7.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 387,925 shares of company stock valued at $233,386,647. Corporate insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Quent Capital LLC acquired a new stake in Medpace in the third quarter valued at approximately $25,000. Optiver Holding B.V. purchased a new stake in shares of Medpace during the 3rd quarter valued at $27,000. Quarry LP purchased a new stake in shares of Medpace during the 3rd quarter valued at $35,000. Root Financial Partners LLC acquired a new stake in shares of Medpace in the 3rd quarter worth $38,000. Finally, Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.